170 related articles for article (PubMed ID: 36971495)
21. Genomics in upper tract urothelial carcinoma.
Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of HER2 expression in urothelial carcinoma.
Rosli N; Mahasin M; Mohd Saleh MF; Abd Shukor N
Malays J Pathol; 2022 Aug; 44(2):245-252. PubMed ID: 36043587
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder.
Chen X; Wu B; Xu Z; Li S; Tan S; Liu X; Wang K
Cancer Med; 2016 Aug; 5(8):1856-62. PubMed ID: 27292588
[TBL] [Abstract][Full Text] [Related]
24. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder.
Olsson H; Fyhr IM; Hultman P; Jahnson S
Scand J Urol Nephrol; 2012 Apr; 46(2):102-7. PubMed ID: 22150625
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.
Li J; Liang Y; Fan J; Xu C; Guan B; Zhang J; Guo B; Shi Y; Wang P; Tan Y; Zhang Q; Yuan C; Wu Y; Zhou L; Ci W; Li X
BMC Med; 2022 Jul; 20(1):222. PubMed ID: 35843958
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
[TBL] [Abstract][Full Text] [Related]
27. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review.
van Doeveren T; van de Werken HJG; van Riet J; Aben KKH; van Leeuwen PJ; Zwarthoff EC; Boormans JL
Urol Oncol; 2020 Jun; 38(6):590-598. PubMed ID: 32057596
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.
Kolla SB; Seth A; Singh MK; Gupta NP; Hemal AK; Dogra PN; Kumar R
Int Urol Nephrol; 2008; 40(2):321-7. PubMed ID: 17899426
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
30. Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
Wu J; Jin S; Gu C; Wei Y; Zhu Y; Necchi A; Shariat SF; Pan J; Gan H; Dai B; Zhang H; Shi G; Zhu Y; Shen Y; Zhu Y; Ye D
Cell Rep Med; 2023 Jan; 4(1):100883. PubMed ID: 36630951
[TBL] [Abstract][Full Text] [Related]
31. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
[TBL] [Abstract][Full Text] [Related]
32. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
33. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H
Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533
[TBL] [Abstract][Full Text] [Related]
34. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer.
Soria F; Moschini M; Haitel A; Wirth GJ; Gust KM; Briganti A; Rouprêt M; Klatte T; Hassler MR; Karakiewicz PI; Shariat SF
Urol Oncol; 2016 Dec; 34(12):533.e1-533.e10. PubMed ID: 27665356
[TBL] [Abstract][Full Text] [Related]
35. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
Ching CB; Amin MB; Tubbs RR; Elson P; Platt E; Dreicer R; Fergany A; Hansel DE
Mod Pathol; 2011 Aug; 24(8):1111-9. PubMed ID: 21516078
[TBL] [Abstract][Full Text] [Related]
36. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
37. Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.
Anno T; Kikuchi E; Shigeta K; Ogihara K; Watanabe K; Yanai Y; Takamatsu K; Hasegawa S; Masuda T; Oyama M; Mizuno R; Oya M
Jpn J Clin Oncol; 2021 May; 51(6):984-991. PubMed ID: 33589927
[TBL] [Abstract][Full Text] [Related]
38. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
Yang F; Zhou Q; Meng L; Xing N
Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
[TBL] [Abstract][Full Text] [Related]
39. High MT2A Expression Predicts Worse Prognosis in Patients with Urothelial Carcinoma.
Li WM; Ke HL; Kuo YH; Lai HY; Chan TC; Hsing CH; Hsieh KL; Li WS; Chen TJ; Wei YC; Wu WJ; Huang SK; Li CF
Oncology; 2022; 100(9):485-497. PubMed ID: 35817020
[No Abstract] [Full Text] [Related]
40. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
